Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) Shares Outstanding (Weighted Average): 2013-2024

Historic Shares Outstanding (Weighted Average) for Ascendis Pharma A (ASND) over the last 12 years, with Dec 2024 value amounting to $57.5 million.

  • Ascendis Pharma A's Shares Outstanding (Weighted Average) rose 5.60% to $60.6 million in Q3 2025 from the same period last year, while for Dec 2024 it was $57.5 million, marking a year-over-year decrease of 0.21%. This contributed to the annual value of $57.5 million for FY2024, which is 0.21% down from last year.
  • Ascendis Pharma A's Shares Outstanding (Weighted Average) amounted to $57.5 million in FY2024, which was down 0.21% from $57.7 million recorded in FY2023.
  • Ascendis Pharma A's Shares Outstanding (Weighted Average)'s 5-year high stood at $57.7 million during FY2023, with a 5-year trough of $52.7 million in FY2020.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $57.4 million, with a median of $57.5 million in 2024.
  • In the last 5 years, Ascendis Pharma A's Shares Outstanding (Weighted Average) rose by 10.42% in 2020 and then declined by 0.21% in 2024.
  • Yearly analysis of 5 years shows Ascendis Pharma A's Shares Outstanding (Weighted Average) stood at $52.7 million in 2020, then grew by 2.11% to $53.8 million in 2021, then grew by 5.94% to $57.0 million in 2022, then grew by 1.10% to $57.7 million in 2023, then dropped by 0.21% to $57.5 million in 2024.